|
|
|
|
Vol. 60, Issue 6, 1332-1342, December 2001
Institute of Clinical Pharmacology and Toxicology, Benjamin
Franklin Medical Center, Freie Universität, Berlin, (H.-D.O.,
A.G., S.M., A.Z., H.F.-K., R.R., F.S.Z., M.P.), and Main Laboratory,
BASF AG, Ludwigshafen, Germany (T.S.)
Isoform-specific expression of endothelin-converting enzyme (ECE)-1,
the major big endothelin-processing enzyme, is controlled by
alternative promoters. Signaling pathways and transcriptional mechanisms of ECE-1 mRNA expression are largely unknown. To investigate ECE-1 isoform expression after protein kinase C (PKC) activation, we
used phorbol 12-myristate 13-acetate (PMA) to stimulate primary cultured human umbilical vein endothelial cells and the related EA.hy926 cell line. ECE-1a mRNA was up-regulated (approximately 3-fold), whereas mRNA of alternative isoforms (b, c, and d) was unchanged, which was confirmed on the protein level. PMA effects on
mRNA expression were suppressed by the PKC inhibitors H-7 and Calphostin C. Because increased ECE-1a expression was preceded by
induction of the transcription factor Ets-1, we performed gel shift
assays and demonstrated specific DNA/protein interactions involving the
ETS binding motif GGAA. Luciferase reporter assays showed that PMA
induced ECE-1a promoter activity about 2.5-fold in EA.hy926 cells.
Similarly, coexpression of Ets-1 protein resulted in a dose-dependent
increase in ECE-1a promoter activity (more than 8-fold). Using gel
shift assays and mutation analysis, we identified two tandemly arranged
Ets-1 binding sites (EBS) at
638 and
658, respectively, that are
involved in transcriptional activation of the ECE-1a promoter by PMA or
Ets-1. Moreover, we also found evidence for binding of a
transcriptional repressor to EBS
638. The inhibitor of
mitogen-activated protein kinase kinase, PD98059, inhibited PMA effects
on ECE-1a mRNA expression and promoter activity, respectively. Our
results provide the first detailed analysis of signaling pathways and
transcriptional mechanisms involved in isoform-specific
ECE-1 gene expression.
This article has been cited by other articles:
![]() |
M. Khamaisi, R. Dahan, S. Hamed, Z. Abassi, S. N. Heyman, and I. Raz Role of Protein Kinase C in the Expression of Endothelin Converting Enzyme-1 Endocrinology, March 1, 2009; 150(3): 1440 - 1449. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. R. Kaufman and J. L. Minion Pharmacological characterization of the ergot alkaloid receptor in the salivary gland of the ixodid tick Amblyomma hebraeum J. Exp. Biol., July 1, 2006; 209(13): 2525 - 2534. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Fisk, N. N. Nalivaeva, and A. J. Turner Regulation of endothelin-converting enzyme-1 expression in human neuroblastoma cells. Experimental Biology and Medicine, June 1, 2006; 231(6): 1048 - 1053. [Abstract] [Full Text] [PDF] |
||||
![]() |
D.-S. Choi, D. Wang, G.-Q. Yu, G. Zhu, V. N. Kharazia, J. P. Paredes, W. S. Chang, J. K. Deitchman, L. Mucke, and R. O. Messing From the Cover: PKC{varepsilon} increases endothelin converting enzyme activity and reduces amyloid plaque pathology in transgenic mice PNAS, May 23, 2006; 103(21): 8215 - 8220. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Muller, A. Barret, E. Etienne, R. Meidan, O. Valdenaire, P. Corvol, and C. Tougard Heterodimerization of Endothelin-converting Enzyme-1 Isoforms Regulates the Subcellular Distribution of This Metalloprotease J. Biol. Chem., January 3, 2003; 278(1): 545 - 555. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. J. MacLeod, R. D. Husain, D. A. Gage, and K. Ahn Constitutive Phosphorylation of Human Endothelin-converting Enzyme-1 Isoforms J. Biol. Chem., November 22, 2002; 277(48): 46355 - 46363. [Abstract] [Full Text] [PDF] |
||||